BiomX Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PHGE NYSE American 2836 www.biomx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BiomX Inc.

BiomX announces $3M private placement - Dec 30th, 2025 6:15 am
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy - Dec 29th, 2025 10:00 am
BiomX Announces $3.0 Million Private Placement - Dec 29th, 2025 6:00 am
Sector Update: Health Care Stocks Fall Late Afternoon - Dec 8th, 2025 2:01 pm
Top Midday Decliners - Dec 8th, 2025 12:11 pm
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review - Dec 8th, 2025 5:30 am
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis - Nov 25th, 2025 2:40 pm
BiomX Inc. Announces 1-for-19 Reverse Stock Split - Nov 14th, 2025 2:31 pm
BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Nov 12th, 2025 2:02 pm
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates - Nov 12th, 2025 5:30 am
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025 - Nov 5th, 2025 6:30 am
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections - Nov 4th, 2025 6:40 am
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways - Oct 17th, 2025 6:30 am
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference - Sep 4th, 2025 6:30 am
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis - Aug 19th, 2025 6:19 am
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates - Aug 13th, 2025 4:30 am
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 - Aug 6th, 2025 6:30 am
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis - Jul 14th, 2025 7:00 am
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis - Jul 8th, 2025 6:30 am
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference - May 19th, 2025 8:02 am